Scientists dive deep into liver immune cells to unlock NASH secrets

NCT ID NCT06152250

Recruiting now Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at the immune cells inside the liver of people with non-alcoholic fatty liver disease (NAFLD). The goal is to find differences between those with simple fatty liver and those with the more serious form, NASH, which can lead to cirrhosis and liver cancer. Researchers will use a special needle to collect a small sample of liver cells from 60 participants during a routine biopsy. By analyzing these cells, they hope to better understand what drives NASH and identify potential targets for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could reveal new targets for future treatments for NASH, a serious liver condition.
What could go wrong: This is a small, early-stage observational study, not a treatment trial. It may not lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis liver disorder metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER DISEASES

Contacts and locations

Locations

Service Hepato Gastrologie
RECRUITING

Lyon, Auvergne-Rhône-Alpes, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.